Loading stock…

Phibro Animal Health Corporation (PAHC) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Phibro Animal Health Corporation

PAHCMarket cap $1.53BPrice $37.7

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Makes vaccines, medicated feed additives, and health products that keep livestock and poultry disease-free worldwide. Nearly every chicken nugget and steak you eat likely passed through their animal health products first.

In Bastion Portfolios?

52W Return-5%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+16%8

Revenue Forecast

Rev CAGR (1y)+4%4

Rev CAGR (3y)+3%3

Rev CAGR (5y)+3%3

Earnings Forecast

EPS Growth Y+1+44%9

EPS Growth Y+2+9%6

EPS Growth Y+3+8%6

Quality

Margins

EBIT Margin13%5

Net Income Margin7%4

Free Cash Flow Margin1%3

Debt

Net Debt/EBITDA2.73

Efficiency

ROE30%9

ROA7%7

Earnings Stability55

GEAR+AVERAGE35

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)118

P/E Ratio (Forward 3y)98

P/BV4.04

EV Multiples

EV/EBITDA Fwd97

EV/EBIT Fwd108

Yield

Free Cash Flow Yield0.6%3

Dividend Yield1.3%4

Momentum

Short term

1 month return+1%8

3 month return+17%9

YTD return+2%5

Mid term

Price vs 52wHigh63%3

1 year return+3%5

Long term

3 year return+215%9

5 year return+94%7

Risk Shield

Price Risk

Beta0.67

Volatility56%2

Free Cash Flow

Free Cash Flow Margin1%3

Free Cash Flow Yield0.6%3

Quality

ROCE17%8

Earnings Stability55

Net Debt/EBITDA2.73

02Growth

Is it actually growing, and how fast?

PAHCPhibro Animal Health

Revenue FY26$1.5B

GROWTH RATING↗

WEAK34 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+3%3

Revenue, next 5Y, CAGR+3%3

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+44%9

EPS growth, FY28E+9%6

EPS growth, FY29E+8%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Earnings are set to grow faster than sales (EPS about 9%/yr vs revenue 3%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 34% of companies worldwide.

Revenue grew 16%/yr over the last 3 years; forecasts see it cooling to 3%/yr.

WEAKNESSES

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 3%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG70 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return+17%9

YTD return+2%5

MID & LONG-TERM▾SCORE

% of 52-week high63%3

1-year return+3%5

3-year return+215%9

5-year return+94%7

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +215% over three years and +94% over five, ahead of 70% of the market.

Strong recent results. The stock is outperforming over the past month (+1%) and over three months (+17%).

WATCH

It's up 3% over the past year, but 37% below its 52-week high. That is a touch behind the market.

Returns sit at the market level so far this year (+2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Phibro Animal Health Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

PAHCPhibro Animal Health

Revenue FY26$1.5B

GROWTH RATING↗

WEAK34 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+3%3

Revenue, next 5Y, CAGR+3%3

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+44%9

EPS growth, FY28E+9%6

EPS growth, FY29E+8%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Earnings are set to grow faster than sales (EPS about 9%/yr vs revenue 3%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 34% of companies worldwide.

Revenue grew 16%/yr over the last 3 years; forecasts see it cooling to 3%/yr.

WEAKNESSES

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 3%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG70 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return+17%9

YTD return+2%5

MID & LONG-TERM▾SCORE

% of 52-week high63%3

1-year return+3%5

3-year return+215%9

5-year return+94%7

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +215% over three years and +94% over five, ahead of 70% of the market.

Strong recent results. The stock is outperforming over the past month (+1%) and over three months (+17%).

WATCH

It's up 3% over the past year, but 37% below its 52-week high. That is a touch behind the market.

Returns sit at the market level so far this year (+2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Phibro Animal Health Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community